Want to join the conversation?
Leerink Partners analyst Geoffrey Porges questions $GILD whether there is a stable outlook for HCV revenue on a market-by-market basis from its historic lows. COO Kevin Young says that there will be a gradual decline in new patient starts, but the company will, after copious amounts of testing and diagnoses with the CDC, hit an equilibrium.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?